NCT07075471

Brief Summary

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
13mo left

Started Sep 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress46%
Sep 2025Sep 2027

First Submitted

Initial submission to the registry

July 11, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 20, 2025

Completed
2 months until next milestone

Study Start

First participant enrolled

September 3, 2025

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2027

Last Updated

July 27, 2026

Status Verified

July 1, 2026

Enrollment Period

2 years

First QC Date

July 11, 2025

Last Update Submit

July 24, 2026

Conditions

Tenosynovial Giant Cell Tumor

Outcome Measures

Primary Outcomes (2)

  • Duration of Vimseltinib Treatment

    Baseline up to 12 months

  • Time to Discontinuation of Vimseltinib

    Baseline to Discontinuation (Estimated up to 12 months)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants being treated for TGCT with vimseltinib in the community setting.

You may qualify if:

  • Diagnosis of TGCT according to medical records
  • Prescribed vimseltinib per the approved label requirements, OR The decision to receive vimseltinib has been made but treatment has not yet been initiated.
  • Has provided informed consent and medical records release

You may not qualify if:

  • \. Participant is active in an interventional clinical trial of vimseltinib

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Synexus Clinical Research, US INC

Wilmington, North Carolina, 28401, United States

RECRUITING

MeSH Terms

Conditions

Giant Cell Tumor of Tendon Sheath

Condition Hierarchy (Ancestors)

Giant Cell TumorsNeoplasms, Connective TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsSynovitisJoint DiseasesMusculoskeletal DiseasesTendinopathyMuscular Diseases

Study Officials

  • Clinical Team

    Deciphera Pharmaceuticals, LLC

    STUDY DIRECTOR

Central Study Contacts

Clinical Team

CONTACT

888-724-3274clinicaltrials@deciphera.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 11, 2025

First Posted

July 20, 2025

Study Start

September 3, 2025

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2027

Last Updated

July 27, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share

Locations

US(1)